Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

NCT00124527 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Irofulven + capecitabine

Sponsor

Eisai Inc.